Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.50 |
| ▸ | TGFBR2 | P37173 | 8/20 | 0.48 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | GRK5 | P34947 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084058 | 0.80 | TGFBR1 (0.60) | TGFBR1TGFBR2 | |
| SCHEMBL16531904 | 0.76 | TNF (0.54) | TGFBR1TGFBR2 | |
| SCHEMBL25941168 | 0.76 | FYN (0.53) | TGFBR1TGFBR2FYN | |
| SCHEMBL23872992 | 0.76 | AURKA (0.52) | TGFBR1TGFBR2 | |
| SCHEMBL20625676 | 0.76 | TGFBR1 (0.56) | TGFBR1TGFBR2 | |
| SCHEMBL13080301 | 0.76 | FYN (0.38) | FYNGRK5 | |
| SCHEMBL2066640 | 0.73 | TNF (0.61) | TGFBR1FYNGRK5 | |
| SCHEMBL13080168 | 0.72 | FYN (0.35) | FYNGRK5 | |
| SCHEMBL13080172 | 0.72 | FYN (0.40) | FYNGRK5 | |
| SCHEMBL21637233 | 0.71 | HTT (0.46) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
| WO-2020041562-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TGFBR1 1681/4885TGFBR2 3186/4885FYN 2188/4885 |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | TGFBR1 2/4885TGFBR2 4/4885FYN 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.